TopoTarget's 2nd-qtr loss widens to $17.1M
Copenhagen, Denmark-based TopoTarget AS says that, for the six months ended June 30, 2007, operating loss amounted to 93.7 million Danish kroner ($17.1 million) versus 86.6 million in the year-earlier period, as loss before tax reached 91.2 million kroner vs 84.4 million kroner, which corresponded to a loss per share of 1.96 kroner vs 2.04 per share.
TopoTarget's operating highlights during the period, included its share-based acquisition of privately-held Swiss biotechnology firm Apoxis SA, gaining two first-in-class oncology drug candidates in Phase I and Phase II development, as well as enhancing its protein drug R&D.
Savene sales total 4.6M kroner
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze